Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles

Journal of Controlled Release

Volumn 157, Issue 3, 2012, Pages 366-374

  Fonge, Humphrey ^a   Huang, Huang ^a   Scollard, Deborah ^a   Reilly, Raymond M ^a,b,c   Allen, Christine ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bifunctional chelators (BFCs); Block copolymer micelles (BCMs); Human epidermal growth factor (hEGF); Indium 111; Pharmacokinetics

Indexed keywords

BIFUNCTIONAL; BIODISTRIBUTIONS; BLOCK COPOLYMER MICELLES; BLOCK COPOLYMER MICELLES (BCMS); BLOOD CONCENTRATIONS; EPIDERMAL GROWTH FACTORS; EPR EFFECT; HALF LIVES; HIGH DENSITY; HUMAN BREAST CANCER; HUMAN EPIDERMAL GROWTH FACTOR; INDIUM-111; LOWER DENSITY; NON-TARGETED; ORGAN DISTRIBUTION; PHARMACOKINETIC PARAMETERS; PHYSICOCHEMICAL CHARACTERISTICS; RADIOLABELLING; TAIL VEINS; TUMOR UPTAKE; TWO-COMPARTMENT MODELS; WHOLE BODY;

BLOCK COPOLYMERS; CHELATION; MAMMALS; MICELLES;

PHARMACOKINETICS;

1,4,7.10 TETRAAZACYCLODODECANE 1,4,7,10-TETRAACETIC ACID MONO (1 HYDROXYSUCINIMIDE ESTER); 2(4 ISOTHIOCYANATOBENZYL) DIETHYLENETRIAMINEPENTAACETIC ACID; 2(4 ISOTHIOCYANATOBENZYL) DIETHYLENETRIAMINEPENTAACETIC ACID METHOXYPOLY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER IN 111; 2(4 THIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRATACETIC ACID; 2(4 THIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRATACETIC ACID METHOXYPOLY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER IN 111; ACID ANHYDRIDE; COPOLYMER; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA UROGASTRONE; GAMMA UROGASTRONE 2(4 ISOTHIOCYANATOBENZYL) DIETHYLENETRIAMINEPENTAACETIC ACID METHOXYPOLY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER IN 111; GAMMA UROGASTRONE 2(4 THIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRATACETIC ACID METHOXYPOLY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER IN 111; GAMMA UROGASTRONE IN 111; GAMMA UROGASTRONE METHOXY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER IN 111; INDIUM 111; METHOXY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER; METHOXY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER IN 111; PENTETIC ACID; POLY (ETHYLENE GLYCOL) BETA POLY (EPSILON CAPROLACTONE); TETRAXETAN; TETRAXETAN METHOXY (ETHYLENE GLYCOL) BLOCK POLYCAPROLACTONE COPOLYMER IN 111; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DENSITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIVER; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SPLEEN; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHELATING AGENTS; CHEMISTRY, PHARMACEUTICAL; EPIDERMAL GROWTH FACTOR; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MICE; MICE, NUDE; MICELLES; NEOPLASM TRANSPLANTATION; PENTETIC ACID; POLYMERS; TISSUE DISTRIBUTION;

EID: 84857313332     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.09.088     Document Type: Article

References (48)

1. S.E. Krown, D.W. Northfelt, D. Osoba, and J.S. Stewart Use of liposomal anthracyclines in Kaposi's sarcoma Semin. Oncol. 31 Suppl. 13 2004 36 52 (Pubitemid 40023241)
2. A.C. Wolff Liposomal anthracyclines and new treatment approaches for breast cancer Oncologist 8 Suppl. 2 2003 25 30 (Pubitemid 37152054)
3. P. Chu, and S. Sadullah The current role of amphotericin B lipid complex in managing systemic fungal infections Curr. Med. Res. Opin. 25 2009 3011 3020
4. S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, D. Jowle, M. Brampton, G. Halbert, and M. Ranson Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer Br. J. Cancer 90 2004 2085 2091 (Pubitemid 38869710)
5. J. Homsi, G.R. Simon, C.R. Garrett, G. Springett, R. De Conti, A.A. Chiappori, P.N. Munster, M.K. Burton, S. Stromatt, C. Allievi, P. Angiuli, A. Eisenfeld, D.M. Sullivan, and A.I. Daud Phase I trial of poly-l-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies Clin. Cancer Res. 13 2007 5855 5861 (Pubitemid 47583911)
6. Y. Matsumura, M. Gotoh, K. Muro, Y. Yamada, K. Shirao, Y. Shimada, M. Okuwa, S. Matsumoto, Y. Miyata, H. Ohkura, K. Chin, S. Baba, T. Yamao, A. Kannami, Y. Takamatsu, K. Ito, and K. Takahashi Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer Ann. Oncol. 15 2004 517 525 (Pubitemid 38444560)
7. Y. Matsumura, T. Hamaguchi, T. Ura, K. Muro, Y. Yamada, Y. Shimada, K. Shirao, T. Okusaka, H. Ueno, M. Ikeda, and N. Watanabe Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 91 2004 1775 1781 (Pubitemid 39664964)
8. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. 4 2005 145 160 (Pubitemid 40282557)
9. V.P. Torchilin Multifunctional nanocarriers Adv. Drug. Deliv. Rev. 58 2006 1532 1555 (Pubitemid 44822608)
10. M. Ferrari Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 5 2005 161 171 (Pubitemid 40314948)
11. 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy Mol. Pharm. 7 2010 177 186
12. H. Lee, B. Hoang, H. Fonge, R.M. Reilly, and C. Allen In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels Pharm. Res. 27 2010 2343 2355
13. J. Zheng, C. Allen, S. Serra, D. Vines, M. Charron, and D.A. Jaffray Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology Contrast Media Mol. Imaging 5 2010 147 154
14. J. Zheng, D. Jaffray, and C. Allen Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model Mol. Pharm. 6 2009 571 580
15. A.S. Mikhail, and C. Allen Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels J. Control. Release 138 2009 214 223
16. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740 (Pubitemid 44085631)
17. C. Mamot, D.C. Drummond, C.O. Noble, V. Kallab, Z. Guo, K. Hong, D.B. Kirpotin, and J.W. Park Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res. 65 2005 11631 11638 (Pubitemid 41821723)
18. K. Maruyama, N. Takahashi, T. Tagawa, K. Nagaike, and M. Iwatsuru Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo FEBS Lett. 413 1997 177 180 (Pubitemid 27348659)
19. K.M. McNeeley, A. Annapragada, and R.V. Bellamkonda Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma Nanotechnology 18 2007 1 11
20. P. Sapra, and T.M. Allen Ligand-targeted liposomal anticancer drugs Prog. Lipid Res. 42 2003 439 462 (Pubitemid 36700404)
21. H. Maeda Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjug. Chem. 21 2010 797 802
22. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
23. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
24. R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer Biodegradable long-circulating polymeric nanospheres Science 263 1994 1600 1603 (Pubitemid 24128361)
25. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318 (Pubitemid 32476118)
26. J.E. Riviere Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1 2009 26 34
27. T.A. ElBayoumi, and V.P. Torchilin Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody Clin. Cancer Res. 15 2009 1973 1980
28. H. Fonge, L.X. Jin, J. Cleynhens, G. Bormans, and A. Verbruggen Tc-99m-tricarbonyl labelled agents for cell labeling: development, biodistribution in normal mice and preliminary in vitro evaluation Bioorg. Med. Chem. 18 2010 396 402
29. S. Chakraborty, and S. Liu (99m)Tc and (111)In-labeling of small biomolecules: bifunctional chelators and related coordination chemistry Curr. Top. Med. Chem. 10 2010 1113 1134
30. G. Liu, and D.J. Hnatowich Labeling biomolecules with radiorhenium: a review of the bifunctional chelators Anticancer Agents Med. Chem. 7 2007 367 377 (Pubitemid 46813472)
31. 114mIn- mediated targeting therapy Eur. J. Nucl. Med. Mol. Imaging 36 2009 1460 1468
32. 111In-labelled block copolymer micelles by high resolution and high sensitivity MicroSPECT/CT imaging Mol. Pharm. 6 2009 581 592
33. F. Zeng, and C. Allen Synthesis of carboxy-functionalized heterobifunctional poly(ethylene glycol) by a thiol-anionic polymerization method Macromolecules 39 2006 6391 6398 (Pubitemid 44555080)
34. F. Zeng, H. Lee, and C. Allen Epidermal growth factor-conjugated poly(ethylene glycol)-block-poly(delta-valerolactone) copolymer micelles for targeted delivery of chemotherapeutics Bioconjug. Chem. 17 2006 399 409
35. X. Zhang, J.K. Jackson, and H.M. Burt Determination of surfactant critical micelle concentration by a novel fluorescence depolarization technique J. Biochem. Biophys. Methods 31 1996 145 150 (Pubitemid 26059157)
36. J. Liu, F. Zeng, and C. Allen In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration Eur. J. Pharm. Biopharm. 65 2007 309 319
37. J. Filmus, M.N. Pollak, R. Cailleau, and R.N. Buick MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF Biochem. Biophys. Res. Commun. 128 1985 898 905 (Pubitemid 15000428)
38. R.E. Kontermann Immunoliposomes for cancer therapy Curr. Opin. Mol. Ther. 8 2006 39 45 (Pubitemid 43230899)
39. 99mTc-chelators influences radiolabeling, stability and biodistribution of affibody molecules Bioorg. Med. Chem. Lett. 19 2009 3912 3914
40. E.N. Sabbah, J. Kadouche, D. Ellison, C. Finucane, D. Decaudin, and S.J. Mather In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer Nucl. Med. Biol. 34 2007 293 304 (Pubitemid 46454375)
41. 111In-Bz-DTPA-hEGF: preparation and in vitro characterization of a potential anti-glioblastoma targeting agent Cancer Biother. Radiopharm. 18 2003 643 654 (Pubitemid 37082385)
42. R.W. Kozak, A. Raubitschek, S. Mirzadeh, M.W. Brechbiel, R.P. Junghans, O.A. Gansow, and T.A. Waldmann Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity Cancer Res. 49 1989 2639 2644 (Pubitemid 19143391)
43. H.R. Maecke, A. Riesen, and W. Ritter The molecular structure of indium-DTPA J. Nucl. Med. 30 1989 1235 1239 (Pubitemid 19175984)
44. B. Gupta, T.S. Levchenko, D.A. Mongayt, and V.P. Torchilin Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo J. Drug Target 13 2005 337 343 (Pubitemid 41683987)
45. J.A. Kamps, and G.L. Scherphof Receptor versus non-receptor mediated clearance of liposomes Adv. Drug Deliv. Rev. 32 1998 81 97 (Pubitemid 28277177)
46. J.W. Park, K. Hong, D.B. Kirpotin, O. Meyer, D. Papahadjopoulos, and C.C. Benz Anti-HER2 immunoliposomes for targeted therapy of human tumors Cancer Lett. 118 1997 153 160 (Pubitemid 27450276)
47. D. Kirpotin, J.W. Park, K. Hong, S. Zalipsky, W.L. Li, P. Carter, C.C. Benz, and D. Papahadjopoulos Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro Biochemistry 36 1997 66 75 (Pubitemid 27024679)
48. J.W. Park, K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U.B. Nielsen, J.D. Marks, D. Moore, D. Papahadjopoulos, and C.C. Benz Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin. Cancer Res. 8 2002 1172 1181 (Pubitemid 35177372)